Ilaria Cutini

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Safety of Prophylactic Anakinra in Patients Treated with CD28-Based CD19 Chimeric Antigen Receptor-T Cells for R/R B-Cell Lymphoma.

Safety of Prophylactic Anakinra in Patients Treated with CD28-Based CD19 Chimeric Antigen Receptor-T Cells for R/R B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: March 14, 2026

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.

Journal: HemaSphere

Published: February 05, 2026

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

Journal: The Lancet. Haematology

Published: December 16, 2025

Real-World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus-Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infectious Diseases Working Party of EBMT.

Real-World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus-Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infectious Diseases Working Party of EBMT.

Journal: Transplant infectious disease : an official journal of the Transplantation Society

Published: October 25, 2025

Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.

Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.

Journal: Blood advances

Published: October 20, 2025

Systemic Inflammation and CAR-T Specific Toxicities as Major Drivers of Nonrelapse Mortality: Analysis from the Italian Prospective Observational CART-SIE Study.

Systemic Inflammation and CAR-T Specific Toxicities as Major Drivers of Nonrelapse Mortality: Analysis from the Italian Prospective Observational CART-SIE Study.

Journal: Transplantation and cellular therapy

Published: October 19, 2025

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 18, 2025

Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study.

Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: May 26, 2025

Downregulation of CD19 Expression Associates With Mantle Cell Lymphoma Relapse Following CAR-T Cell Therapy.

Downregulation of CD19 Expression Associates With Mantle Cell Lymphoma Relapse Following CAR-T Cell Therapy.

Journal: European journal of immunology

Published: April 30, 2025

CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.

CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.

Journal: Haematologica

Published: February 12, 2025

Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.

Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.

Journal: Blood advances

Published: February 05, 2025

Pseudoprogression after CAR-T cell therapy: friend or foe?

Pseudoprogression after CAR-T cell therapy: friend or foe?

Journal: Recenti progressi in medicina

Published: January 22, 2025

Showing 1-12 of 32

Last Updated: 09/26/2026